FLAME 30
176 Reports in Pharmaceuticals
Neurostimulation: Technologies and Global Markets
The global neurostimulation devices market is expected to reach $3.8 billion in 2013 and $4.1 billion in 2018, with a compound annual growth rate (CAGR) of 1.5%.
Histone Deacetylase Inhibitors: Emerging Markets
The global histone deacetylase inhibitor (HDI) market reached $153 million in 2011 and $223.2 million in 2012. This market is expected to be valued at $361.8 million in 2013 and $954.3 million by 2018, a compound annual growth rate (CAGR) of 21.4%.
Antibody Drug Conjugates: Technologies and Global Markets
The global market for ADC drugs reached $179 million in 2012 and $396 million in 2013. The market should reach $2.8 billion in 2018 with a compound annual growth rate (CAGR) of 48.1%.
Over-the-Counter (OTC) Drugs and Dietary Supplements: Global Mark...
The global market for OTC medicines and dietary supplements reached $128.8 billion in 2012. This market is expected to reach to $142.7 billion in 2013 and $189.7 billion in 2018, with a compound annual growth rate (CAGR) of 5.9%.
Drugs for Treating Mental Disorders: Technologies and Global Mark...
The global market for drugs used in mental disorders was $70.1 billion in 2012 and $68.9 billion in 2013. This market is expected to rise at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018.
Global Markets for Generic Drugs
The global generics sector reached $269.8 billion in 2012. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.
Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global...
The global market for circulating tumor cell (CTC) technology reached nearly $2.8 billion in 2012 and $3.7 billion in 2013. This market is estimated to reach nearly $8.9 billion by 2018, demonstrating a compound annual growth rate (CAGR) of 18.9% for the five-year period, 2013 to 2018.
Global Markets and Technologies for Advanced Drug Delivery System...
The global revenue for advanced drug delivery systems is estimated to be $151.3 billion in 2013. In 2018, revenues are estimated to reach nearly $173.8 billion, demonstrating a compound annual growth rate (CAGR) of 2.8%.
In Vitro Toxicity Testing: Technologies and Global Markets
The global in vitro toxicity testing market was valued at $4 billion in 2011 and more than $4.9 billion in 2012. This market is estimated to reach nearly $9.9 billion in 2017, with a compound annual growth rate (CAGR) of 14.7% for the five-year period, 2012 to 2017.
2013 Oncology Research Review
This BCC Research review provides highlights from oncology and other related market research reports published in 2013. It covers topics like uterine cancer, ovarian cancer, cervical cancer, prostrate cancer, and hematological disorders.
2013 Pharmaceuticals Research Review
This BCC Research review provides highlights from pharmaceutical market research reports published in 2013. It covers topics like antithrombotic drugs, anticoagulant drugs, drug device combinations, sexually transmitted diseases, histone methyltransferases, and ubiquitin proteasome.
The Global Influenza Market
The global influenza market will grow from nearly $3.8 billion in 2012 to $4 billion in 2013. Market revenue is forecast to increase at a five-year compound annual growth rate (CAGR) of 8% from 2013 to 2018, totaling nearly $6 billion in 2018.
Excipients in Pharmaceuticals
The global excipient market reached nearly $5.9 billion in 2012. This market is expected to grow to $6.3 billion in 2013 and then to $8.8 billion in 2018, a compound annual growth rate (CAGR) of 6.9% over the five-year period from 2013 to 2018.
Medicines for Smoking Cessation: Global Markets
In 2012, the global smoking cessation medicine market had an estimated value of $2.11 billion. Estimated revenues in 2013 will be $2.12 billion. The market will observe growth after 2013 with a compound annual growth (CAGR) of 3.4% to reach $2.5 billion in 2018.
Global Markets for Contract Pharmaceutical Manufacturing, Researc...
The global market for pharmaceutical and biopharmaceutical contract manufacturing, research and packaging was $219.9 billion in 2012. This market is estimated to reach $242.2 billion in 2013 and $374.8 billion by 2018, a five-year compound annual growth rate (CAGR) of 9.1%.
Global Markets for Vaccine Technologies
Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.
Regenerative Medicines: Bone and Joint Applications
The U.S. market for regenerative medicine products used in bone and joint applications was estimated to total $2.72 billion in 2012 and is projected to increase to $2.73 billion in 2013. The market should total nearly $3.9 billion by 2018 and have a five-year compound annual growth rate (CAGR) of 7.3%.
Ubiquitin Proteasome: Global Markets for Research Tools, Diagnost...
The global market for ubiquitin proteasome research and development was estimated at nearly $2.9 billion in 2013. The market should total more than $5.5 billion by 2018, and have a five-year compound annual growth rate (CAGR) of 14.2% from 2013 to 2018.
Global Markets for Orphan Drugs
The global market for orphan drugs reached nearly $86.1 billion in 2012. The market is expected to reach $112.1 billion in 2017 for a compound annual growth rate (CAGR) of 5.4%.
Skin Disease Treatment Technologies and Global Markets
The global dermatology markets reached $15.8 billion in 2012. The market is expected to reach $16.1 billion in 2013 and $18.5 billion in 2018 for a CAGR of 2.8%.
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
The global market for alzheimer’s disease reached $10.2 billion in 2012. The market is expected to decrease to $9.5 billion in 2017 for a CAGR of -1.5%.
Global Markets for Infectious Disease Treatments
The global market for infectious disease diagnostic, vaccine and pharmaceutical products was $59.2 billion in 2011 and $66.4 billion in 2012. Market growth looks promising, the overall market value for 2017 is projected to be $96.8 billion after increasing at a compound annual growth rate (CAGR) of 7.8%.
Histone Methyltransferases: Global Markets for Research Tools, Di...
The global market for histone methyltransferases research and development was valued at $93 million in 2012 and is expected to reach $118 million in 2013. The market is further expected to grow at a CAGR of 18.4% and reach $275 million by 2018.
Global Markets and Technologies for Pandemic Control
The total market for pandemic infectious disease products broken down by disease type was $31.6 billion in 2011 and $35.6 billion in 2012. The market is expected to rise at a CAGR of 9.3% and reach nearly $55.6 billion by 2017.
Drugs and Diagnostics for Hematological Disorders: Global Markets
The total global market for hematological disorder drugs and diagnostics in 2012 was estimated at nearly $72.9 billion. By 2017, the market is expected to reach $99.1 billion, growing at a compound annual growth rate (CAGR) of 6.4% between 2012 and 2017.
Choose your License
6 Upcoming Reports in Pharmaceuticals
Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question
Report Includes
- An introduction to interleukin-2 (IL-2) and identification of its applications
- Insights of the latest trends and technologies in the IL-2 research and development
- Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
- Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zuirich which is developing a novel oncologic monoclonal antibody that boosts IL-2 but has an improved side-effect profile.
- Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off target effect
- An understanding of various conditions which may develop as an off-target effects in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)
